How findings on the impact of bladder cancer treatment affect clinical decision-making
"Understanding work productivity and activity impairment in the context of the treatment decisions are vital, not just for the provider who has to counsel on treatment benefits and risks, but also to the patient who's making the ultimate decision," says Angela Smith, MD, MS.
In this video, Angela Smith, MD, MS, discusses the implications of findings from the study, “The effect of treatment on work productivity in patients with bladder cancer,” for which she served as a co-author. Smith is a professor of urology and the associate dean for faculty affairs and leadership development at the University of North Carolina, Chapel Hill.
Video Transcript:
Well, I think the implications on a study that looks at how treatments for bladder cancer impact work productivity are about how they make their treatment decisions. I always start my clinical visits with asking patients what their goals of care are. Sometimes that's cure of disease, but in many cases, it might be also the way in which they live their lives, whether it be living independently at home or being able to attend to their job. Understanding work productivity and activity impairment in the context of the treatment decisions are vital, not just for the provider who has to counsel on treatment benefits and risks, but also to the patient who's making the ultimate decision based upon their personal preferences and what their needs are.
So, the implications are wide and very important. This study sheds light on that that aspect, which is often not as well understood [and] not as well studied as are the oncologic outcomes of certain treatments, but they're all important at the end of the day when a patient is making their treatment decision.
This transcription has been edited for clarity.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
